…I am not sure if Teva would have an alternative plan of action.
Their plan of action, such as it is, is to promote thrice-weekly Copaxone as an alternative to regular Copaxone (if the thrice-weekly product has been approved). However, as previously noted on this board, the thrice-weekly product has no medical advantage relative to ordinary Copaxone.
According to Phillip Frost, COB of Teva, they are looking for targeted partnership and acquisition in MS and respiratory areas. The problem is MS drug development process is very very long, unless the drug candidate is in ph3 development already, it is at minimum 6-7 years away from market.
Market Data 
Markets 
AI
